Pharma BD Deal Intelligence

Allergan plc / Naurex, Inc.

2015 · Acquisition/Merger · $560M · Complete

Announcement Sentiment

Negative

Allergan acquired Naurex for $560M upfront net of cash plus undisclosed R&D and sales-threshold milestones, gaining rapastinel and NRX-1074, novel NMDA modulators for depression. Closed August 31, 2015. Rapastinel later failed Phase 3 in 2019.

Key facts

Announced Jul 26, 2015
Closed Aug 31, 2015
Deal value $560M
Deal type Acquisition/Merger
Therapeutic area Major depressive disorder (treatment-resistant)
Indications Major depressive disorder (treatment-resistant)
Key assets Rapastinel (GLYX-13); NRX-1074
Mechanism NMDA receptor modulator (allosteric)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals